PMID- 34241785
OWN - NLM
STAT- MEDLINE
DCOM- 20220722
LR  - 20220722
IS  - 2095-0225 (Electronic)
IS  - 2095-0217 (Linking)
VI  - 16
IP  - 3
DP  - 2022 Jun
TI  - Proteomics study of Mycoplasma pneumoniae pneumonia reveals the Fc fragment of 
      the IgG-binding protein as a serum biomarker and implicates potential therapeutic 
      targets.
PG  - 378-388
LID - 10.1007/s11684-021-0840-y [doi]
AB  - Macrolide and corticosteroid resistance has been reported in patients with 
      Mycoplasma pneumoniae (MP) pneumonia (MPP). MP clearance is difficult to achieve 
      through antibiotic treatment in sensitive patients with severe MPP (SMPP). SMPP 
      in children might progress to airway remodeling and even bronchiolitis/bronchitis 
      obliterans. Therefore, identifying serum biomarkers that indicate MPP progression 
      and exploring new targeted drugs for SMPP treatment require urgency. In this 
      study, serum samples were collected from patients with general MPP (GMPP) and 
      SMPP to conduct proteomics profiling. The Fc fragment of the IgG-binding protein 
      (FCGBP) was identified as the most promising indicator of SMPP. Biological 
      enrichment analysis indicated uncontrolled inflammation in SMPP. ELISA results 
      proved that the FCGBP level in patients with SMPP was substantially higher than 
      that in patients with GMPP. Furthermore, the FCGBP levels showed a decreasing 
      trend in patients with GMPP but the opposite trend in patients with SMPP during 
      disease progression. Connectivity map analyses identified 25 possible targeted 
      drugs for SMPP treatment. Among them, a mechanistic target of rapamycin kinase 
      (mTOR) inhibitor, which is a macrolide compound and a cell proliferation 
      inhibitor, was the most promising candidate for targeting SMPP. To our knowledge, 
      this study was the first proteomics-based characterization of patients with SMPP 
      and GMPP.
CI  - (c) 2021. Higher Education Press.
FAU - Liu, Jinrong
AU  - Liu J
AD  - Department of Respiratory Medicine, Beijing Children's Hospital, Capital Medical 
      University, National Center for Children's Health, Beijing, 100045, China.
FAU - Shen, Rongfang
AU  - Shen R
AD  - State Key Laboratory of Molecular Oncology, Department of Etiology and 
      Carcinogenesis, National Cancer Center/National Clinical Research Center for 
      Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, 100021, China.
FAU - Feng, Lin
AU  - Feng L
AD  - State Key Laboratory of Molecular Oncology, Department of Etiology and 
      Carcinogenesis, National Cancer Center/National Clinical Research Center for 
      Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, 100021, China.
FAU - Cheng, Shujun
AU  - Cheng S
AD  - State Key Laboratory of Molecular Oncology, Department of Etiology and 
      Carcinogenesis, National Cancer Center/National Clinical Research Center for 
      Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, 100021, China.
FAU - Chen, Jun
AU  - Chen J
AD  - Beijing Engineering Research Center of Pediatric Surgery, Engineering and 
      Transformation Center, Beijing Children's Hospital, Capital Medical University, 
      National Center for Children's Health, Beijing, 100045, China. 
      xixiangchenjun@163.com.
FAU - Xiao, Ting
AU  - Xiao T
AD  - State Key Laboratory of Molecular Oncology, Department of Etiology and 
      Carcinogenesis, National Cancer Center/National Clinical Research Center for 
      Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, 100021, China. xiaot@cicams.ac.cn.
FAU - Zhao, Shunying
AU  - Zhao S
AD  - Department of Respiratory Medicine, Beijing Children's Hospital, Capital Medical 
      University, National Center for Children's Health, Beijing, 100045, China. 
      zhaoshunying2001@126.com.
LA  - eng
PT  - Journal Article
DEP - 20210709
PL  - China
TA  - Front Med
JT  - Frontiers of medicine
JID - 101549428
RN  - 0 (Biomarkers)
RN  - 0 (Carrier Proteins)
RN  - 0 (Immunoglobulin Fc Fragments)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Macrolides)
SB  - IM
MH  - Biomarkers
MH  - Carrier Proteins
MH  - Child
MH  - Humans
MH  - Immunoglobulin Fc Fragments
MH  - Immunoglobulin G
MH  - Macrolides
MH  - *Mycoplasma pneumoniae
MH  - *Pneumonia, Mycoplasma/drug therapy
MH  - Proteomics
OTO - NOTNLM
OT  - Fc fragment of the IgG-binding protein
OT  - children
OT  - mechanistic target of rapamycin kinase inhibitor
OT  - proteomics
OT  - severe Mycoplasma pneumoniae pneumonia
EDAT- 2021/07/10 06:00
MHDA- 2022/07/23 06:00
CRDT- 2021/07/09 12:24
PHST- 2020/10/26 00:00 [received]
PHST- 2020/11/24 00:00 [accepted]
PHST- 2021/07/10 06:00 [pubmed]
PHST- 2022/07/23 06:00 [medline]
PHST- 2021/07/09 12:24 [entrez]
AID - 10.1007/s11684-021-0840-y [pii]
AID - 10.1007/s11684-021-0840-y [doi]
PST - ppublish
SO  - Front Med. 2022 Jun;16(3):378-388. doi: 10.1007/s11684-021-0840-y. Epub 2021 Jul 
      9.